Tumour spheroids: every input is public-priced and the finished plate is not sold

A multicellular tumour spheroid reintroduces the two things a monolayer removes and that most oncology compounds actually have to survive: a diffusion gradient producing a hypoxic, quiescent core, and cell-to-cell contact that changes drug sensitivity outright. That is why the format exists. It is also why the format is easier to build than to buy.

The commercial position is unusual and it is good news. Every physical input carries a live public price. Immortalised cancer lines are catalogue items at a flat published rate. Microwell and hanging-drop plasticware engineered specifically to produce size-uniform spheroids is publicly priced per plate. Microfluidic chips supporting an ECM-embedded tumour compartment are publicly priced per chip.

What is not purchasable is a released plate of size-specified, viability-verified spheroids of a named line, and still less a patient-derived one, which carries a licensing problem heavy enough that it is covered separately rather than repeated here.

For immortalised-line work, the honest recommendation is usually to assemble. The components are cheap relative to any custom programme, and the uniformity problem a vendor would otherwise solve for you is exactly what the microwell plasticware is engineered to solve.

What is purchasable today, plainly

The decision that actually matters: microcavity diameter

This is the section worth the page.

Spheroid diameter determines whether a hypoxic core forms at all, and diameter is set by the microwell geometry chosen at purchase. It is not adjustable afterwards.

The literature is explicit about the consequence. Work on colorectal spheroids grown to different sizes identified three distinct stages corresponding to defined spheroid sizes: normoxia, hypoxia, and hypoxia plus necrosis, and found that spheroids including both hypoxic and necrotic regions most closely mimicked the gene expression profiles of in vivo-developing tumours and displayed the highest resistance to 5-fluorouracil.

Read that as a procurement statement rather than a biology statement. If you buy a plate that produces uniform spheroids below the size at which gradients appear for your line, you have bought a very reproducible model of the thing you were trying to get away from. It will behave more like a monolayer than like a tumour, it will look immaculate under the microscope, and it will systematically overestimate drug sensitivity.

The plasticware vendors publish microcavity diameters to the micrometre. The assay literature publishes the sizes at which gradients appear. Nothing connects the two at the point of sale.

Two cautions on using that table. First, microcavity diameter constrains but does not equal final spheroid diameter, seeding density, line and culture duration all move it. Second, the size at which hypoxia or necrosis appears is line-dependent, driven by the oxygen consumption rate of the cells, which has itself been treated quantitatively in the literature. There is no universal threshold, and anyone who quotes you one has skipped the hard part.

The correct sequence is therefore: decide whether the study needs a hypoxic core, find or measure the size at which your line develops one, then choose the microcavity geometry, in that order, before buying a plate.

Uniformity is not cosmetic

A second finding from the literature that changes how you should read a quote or design a run: spheroid volume and shape are themselves sources of variability in therapeutic screening data, and pre-selection of spheroids of homogeneous volume and shape is needed before a cytotoxicity test to reduce that variability to a minimum. The same work validated a cytotoxicity assay capable of giving meaningful data on large tumour spheroids up to 650 µm in diameter.

Two consequences.

The plasticware is doing statistical work, not just convenience work. The reason a microwell plate costs $59.75 rather than a few dollars is that it produces one spheroid per cavity at a controlled size, which is what removes volume and shape as confounders. Forming spheroids by low-attachment round-bottom improvisation saves money and reintroduces exactly the variability the literature says to pre-select against.

Assay compatibility has a size ceiling. If your spheroids are large enough to be interesting, they may be large enough to break the viability assay. Check the assay’s validated size range against the spheroid you intend to grow, not the other way round.

The self-assembly bill, costed exactly

Unusually for this site, this route can be costed to the cent from public prices. This is a component bill, not a quotation for a finished model.

A first tumour spheroid experiment costs roughly the price of the cell line. One line at $577.00 plus one 5-pack of microplates at $355.00 is under a thousand dollars for hundreds of wells. At $0.62 per well on the 20-pack, or $7.60 per experiment on the chip route, the consumable cost is close to irrelevant next to the labour.

That is the number any custom quote for finished spheroids has to justify itself against, and it is why we generally do not recommend buying this category as a finished object when an immortalised line will do.

Where the self-assembly recommendation stops

It stops at patient-derived material, and the reason is licensing rather than biology.

The dominant adult stem cell organoid technology is licensed apart from the material, and the licence reaches the product, the medium, the method and every application. That is a fundamentally different commercial object from buying a cell line at a published rate, and it cannot be resolved by reading a storefront. Screening services from a protocol licensee exist and cover many cancer types, but the deliverable is a screening result rather than a model you own.

If your programme needs patient-derived material, treat this page’s arithmetic as inapplicable and start from the licence.

For immortalised lines, the licensing question is smaller but not zero: intended use, academic or commercial, decides the licence question, and a service business built on a line whose terms restrict third-party service provision is a problem discovered late and expensively.

What to put in the RFQ, or in your own protocol

• Cell line or patient-derived source, and the licensing position attached to it. Ask this first, not last.
• Target spheroid diameter, which decides the microwell geometry, which cannot be changed after purchase.
• Whether a hypoxic or quiescent core is required, and how it will be demonstrated, staining, gene expression, or a functional readout.
• Monoculture or co-culture with stromal, immune or endothelial cells, and the ratio.
• Matrix requirement, and whether a defined alternative to a tumour-derived basement membrane extract is acceptable. This matters for reproducibility and for regulatory-facing work.
• Number of spheroids, plate format and replicate structure.
• Size uniformity acceptance criterion, with the measurement method, this is what the literature says to pre-select on.
• Assay endpoint and imaging modality, checked against the size range the assay is validated for.
• STR identity authentication. Not optional for cancer lines, and the single cheapest defence against an entire programme being invalidated.
• Intended use, academic or commercial.

Our position

We broker this. Everything delivered through us is made or supplied by a named partner and labelled as such.

Here the broker’s honest position is mostly to talk you out of a purchase. Line selection and a licensing check, plate geometry selected against the spheroid diameter the assay actually needs, and consolidating line, plate and medium onto one order, that is the entire useful contribution for immortalised-line work, and the components are cheap enough that a competent lab should simply buy them.

Where a broker genuinely earns its place is at the two edges: patient-derived material, where the licence rather than the price is the obstacle, and any programme where somebody other than you must hold a size-uniformity or viability acceptance criterion in writing. Nobody publishes that criterion today, which means it has to be negotiated rather than ordered. Send us the specification if that is the part you want handled.